Why These Two Gene-Editing Stocks Just Diverged

Crispr Therapeutics presented promising gene-editing data for its cholesterol treatment CTX310, demonstrating significant dose-dependent reductions, including a 55% decrease in triglycerides and 49% lower LDL cholesterol at the highest dose, though its stock traded sideways. Concurrently, Intellia Therapeutics surged over 4% following positive two-year results for its hereditary angioedema treatment, where 10 of 11 patients were attack-free, despite recent safety concerns from a patient death in a separate trial and analyst caution regarding the competitive landscape and potential commercial uptake.

Analysis

Crispr Therapeutics (CRSP) presented strong Phase 1 data for its gene-editing cholesterol treatment, CTX310, demonstrating dose-dependent ANGPTL3 reductions, with the highest dose achieving a 55% decrease in triglycerides and 49% lower LDL cholesterol. This positions CTX310 as a potential "one-and-done" therapy, competitive with existing and experimental lipid-lowering drugs, leading William Blair to rate CRSP outperform. Despite this positive development and momentum in Casgevy sales, CRSP stock traded sideways.

Intellia Therapeutics (NTLA) saw its stock surge over 4% following positive two-year results for its hereditary angioedema (HAE) treatment, with 10 of 11 patients attack-free, which Leerink Partners termed a "functional cure." This rebound occurred after a 23% drop last week due to a patient death in a separate transthyretin amyloidosis trial, raising safety concerns for its in vivo editing platform.

However, Wedbush analysts noted three HAE patients still experienced attacks, weakening the "one-time cure" proposition, especially against Ionis Pharmaceuticals' Dawnzera, which shows 71% attack-free rates after a year. William Blair maintains a "market perform" rating on NTLA, advising investors to remain on the sidelines due to safety disclosures and the competitive HAE landscape. Crispr also deprioritized its CTX131 solid tumor program, indicating pipeline focus shifts.

Key Decisions for Investors

• Monitor Crispr Therapeutics' CTX310 regulatory progress and Casgevy's sales growth for continued pipeline and commercial strength, Exercise caution with Intellia Therapeutics given recent safety concerns and competitive pressures in the HAE market, Await further details on Intellia's FDA clinical hold letter and assess competitive landscape shifts in gene-editing therapies.